321 related articles for article (PubMed ID: 21505437)
1. Rapid cell-surface prion protein conversion revealed using a novel cell system.
Goold R; Rabbanian S; Sutton L; Andre R; Arora P; Moonga J; Clarke AR; Schiavo G; Jat P; Collinge J; Tabrizi SJ
Nat Commun; 2011; 2():281. PubMed ID: 21505437
[TBL] [Abstract][Full Text] [Related]
2. Selective processing and metabolism of disease-causing mutant prion proteins.
Ashok A; Hegde RS
PLoS Pathog; 2009 Jun; 5(6):e1000479. PubMed ID: 19543376
[TBL] [Abstract][Full Text] [Related]
3. Impact of methionine oxidation as an initial event on the pathway of human prion protein conversion.
Elmallah MI; Borgmeyer U; Betzel C; Redecke L
Prion; 2013; 7(5):404-11. PubMed ID: 24121542
[TBL] [Abstract][Full Text] [Related]
4. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
5. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
6. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells.
Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K
J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286
[TBL] [Abstract][Full Text] [Related]
7. The Prion Concept and Synthetic Prions.
Legname G; Moda F
Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
[TBL] [Abstract][Full Text] [Related]
8. Requirements for mutant and wild-type prion protein misfolding in vitro.
Noble GP; Walsh DJ; Miller MB; Jackson WS; Supattapone S
Biochemistry; 2015 Feb; 54(5):1180-7. PubMed ID: 25584902
[TBL] [Abstract][Full Text] [Related]
9. PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.
Marshall KE; Hughson A; Vascellari S; Priola SA; Sakudo A; Onodera T; Baron GS
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847358
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cell-surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane-bound human prion protein.
DeMarco ML; Daggett V
J Neurochem; 2009 Apr; 109(1):60-73. PubMed ID: 19226372
[TBL] [Abstract][Full Text] [Related]
11. Prion protein and its conformational conversion: a structural perspective.
Surewicz WK; Apostol MI
Top Curr Chem; 2011; 305():135-67. PubMed ID: 21630136
[TBL] [Abstract][Full Text] [Related]
12. Conformational conversion of prion protein in prion diseases.
Zhou Z; Xiao G
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):465-76. PubMed ID: 23580591
[TBL] [Abstract][Full Text] [Related]
13.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
14. Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.
Shikiya RA; Eckland TE; Young AJ; Bartz JC
Prion; 2014; 8(6):415-20. PubMed ID: 25482601
[TBL] [Abstract][Full Text] [Related]
15. Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane.
Goold R; McKinnon C; Rabbanian S; Collinge J; Schiavo G; Tabrizi SJ
J Cell Sci; 2013 Aug; 126(Pt 16):3552-62. PubMed ID: 23813960
[TBL] [Abstract][Full Text] [Related]
16. Protein misfolding cyclic amplification (PMCA): Current status and future directions.
Saá P; Cervenakova L
Virus Res; 2015 Sep; 207():47-61. PubMed ID: 25445341
[TBL] [Abstract][Full Text] [Related]
17. In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate.
Faburay B; Tark D; Kanthasamy AG; Richt JA
Prion; 2014; 8(6):393-403. PubMed ID: 25495764
[TBL] [Abstract][Full Text] [Related]
18. RNAi: a novel strategy for the treatment of prion diseases.
Kong Q
J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323
[TBL] [Abstract][Full Text] [Related]
19. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
20. Generating Bona Fide Mammalian Prions with Internal Deletions.
Munoz-Montesino C; Sizun C; Moudjou M; Herzog L; Reine F; Chapuis J; Ciric D; Igel-Egalon A; Laude H; Béringue V; Rezaei H; Dron M
J Virol; 2016 Aug; 90(15):6963-6975. PubMed ID: 27226369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
